NEW YORK (TheStreet) --Shares of Eli Lilly (LLY) were sinking by 13.36% in pre-market trading on Wednesday, after the company's Alzheimer's drug Solanezumab failed to meet the end goals in its phase three testing.

Eli Lilly stated that the patients treated with the drug did not show a significant slowing of memory loss, as compared to patients taking the placebo. Consequently, Eli Lilly will not seek regulatory approval.

"We are disappointed for all the people within the company who have worked on this project over many years," Eli Lilly CEO John Lechleiter said on CNBC's "Squawk Box" Wednesday morning.

"We are also disappointed for the millions of patients and caregivers still out there looking for something to slow down the progression of this disease, or perhaps prevent it altogether," he continued.

Nevertheless, Eli Lilly will remain committed to Alzheimer's and is in various phases of testing with other drugs. Through those trials, Lechleiter says, the company will obtain all the information it can and apply it to the development of other medicines.

"We will share the data with the scientific community on December 8 at the clinical trials on Alzheimer's disease meeting in San Diego," Lechleiter said.

Furthermore, incoming CEO David Ricks says that Eli Lilly was always poised to move forward with or without Solanezumab.

"We knew it was a high risk and high reward program. We are disappointed with this result, but we have a lot going on beyond Alzheimer's," Ricks stated. "We have a great team here at Lilly focused on that even today with this disappointing news."

Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

The team rates Eli Lilly as a Buy with a ratings score of B+. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and good cash flow from operations. Although the company may harbor some minor weaknesses, the team feels they are unlikely to have a significant impact on results.

You can view the full analysis from the report here: LLY

If you liked this article you might like

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Here's How Eli Lilly Stock Can Regain Its Footing

Here's How Eli Lilly Stock Can Regain Its Footing

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls